CRP and hydrops fetalis: Vericiguat, the oral soluble guanylate cyclase receptor stimulator, not only reduced the composite endpoint of hospitalization for HF or death from cardiovascular causes, but also significantly decreased high-sensitive CRP and serum UA concentrations in patients with HFrEF [60,61].